Results 101 to 110 of about 4,157 (190)

Warfarin‐Associated Bleeding and Thromboembolic Events in Sub‐Saharan Africa: A Systematic Review and Meta‐Analysis

Pharmacoepidemiology and Drug Safety, Volume 34, Issue 10, October 2025.
ABSTRACT Background Warfarin use in Sub‐Saharan Africa is associated with elevated risks of thromboembolic events and bleeding, but precise prevalence estimates are lacking. This systematic review and meta‐analysis aimed to quantify the prevalence of bleeding and thromboembolic events among patients on warfarin in Sub‐Saharan Africa.
Desalegn Getnet Demsie, Zenaw Debasu Addisu, Chernet Tafere, Bereket Bahiru, Malede Berihun Yismaw, Getahun Mihret, Derbew Fikadu Berhe   +6 more
wiley   +1 more source

Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival [PDF]

, 2008
Background We have engaged in an international program designated the Bank On A Cure, which has established DNA banks from multiple cooperative and institutional clinical trials, and a platform for examining the association of genetic variations with ...
Brian Van Ness, Christine Ramos, Majda Haznadar, Antje Hoering, Jeff Haessler, John Crowley, Susanna Jacobus, Martin Oken, Vincent Rajkumar, Philip Greipp, Bart Barlogie, Brian Durie, Michael Katz, Gowtham Atluri, Gang Fang, Rohit Gupta, Michael Steinbach, Vipin Kumar, Richard Mushlin, David Johnson, Gareth Morgan, ES Lander, JC Venter, International Human Genome Consortium, RA Kyle, PL Bergsagel, JD Shaughnessy, MW Jenner, WJ Chng, NE Kay, MM Oken, B Barlogie, PD Stenson, T Zhao, HJ Kang, RD Miller, KR Ahmadi, P Hardenbol, M Kearns, Valentin Dinu, Ian H Witten, Terry M Therneau, A Agreti, L Breiman, B Efron, EL Kaplan, MD Shriver, C Kawamura, IU Schraufstatter, N Yanamandra, M Bamshad, RK Dasgupta, C Zheng, JR Long, A Li, SW Kim, N Fukushima, Y Alvarado, L Hu, MA van der Pol   +59 more
core   +1 more source

Changes in Protein Expression of Renal Drug Transporters and Drug‐Metabolizing Enzymes in Autosomal Dominant Polycystic Kidney Disease Patients

Clinical Pharmacology &Therapeutics, Volume 118, Issue 3, Page 682-692, September 2025.
Autosomal dominant polycystic kidney disease is the most prevalent inherited kidney disease and leads to bilateral kidney enlargement and progressive loss of renal function, often over decades. Comorbidities include hypertension, flank pain, and bacterial infections. The condition often necessitates prolonged multidrug therapy.
Annika C. Tillmann, Dorien J. M. Peters, Amin Rostami‐Hodjegan, Patricia Wilson, Jill Norman, Jill Barber, Zubida M. Al‐Majdoub   +6 more
wiley   +1 more source

An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease. [PDF]

PLoS ONE, 2012
Appropriate dosing of coumarins is difficult to establish, due to significant inter-individual variability in the dose required to obtain stable anticoagulation. Several genetic and other clinical factors have been associated with the coumarins dose, and
Alberto M Borobia, Rubin Lubomirov, Elena Ramírez, Alicia Lorenzo, Armando Campos, Raul Muñoz-Romo, Carmen Fernández-Capitán, Jesús Frías, Antonio J Carcas   +8 more
doaj   +1 more source

Variability in intestinal drug metabolizing enzymes and transporters in Crohn's disease and potential impact on oral drug absorption

British Journal of Clinical Pharmacology, Volume 91, Issue 7, Page 2028-2044, July 2025.
Aims The aim of study was to generate quantitative data on the abundance of drug‐metabolizing enzymes and transporters (DMETs) in inflamed and non‐inflamed Crohn's disease (CD) ileum and colon, for incorporation into physiologically based pharmacokinetic (PBPK) models, enabling prediction of oral drugs' pharmacokinetics (PK) perturbation in CD patients.
Sarah Alrubia, Brahim Achour, Zubida M. Al‐Majdoub, Amin Rostami‐Hodjegan, Jill Barber   +4 more
wiley   +1 more source

Association of the CYP4F2 rs2108622 genetic polymorphism with hypertension: a meta-analysis

Genetics and Molecular Research, 2015
Previous case-control studies on the relationship between the CYP4F2 gene rs2108622 polymorphism and hypertension have produced contrasting results. In this study, we aimed to further evaluate the relationship between the CYP4F2 gene rs2108622 polymorphism and hypertension.
X-H, Luo, G-R, Li, H-Y, Li
openaire   +2 more sources

Introgression of Brown Norway \u3cem\u3eCYP4A\u3c/em\u3e Genes onto the Dahl Salt-Sensitive Background Restores Vascular Function in SS-5\u3csup\u3eBN\u3c/sup\u3e Consomic Rats [PDF]

, 2013
The present study tested the hypothesis that the Dahl SS (salt-sensitive) rat has vascular dysfunction due, in part, to the up-regulation of the CYP4A/20-HETE (cytochrome P450 ω-hydroxylase 4A)/20-hydroxyeicosatetraenoic acid) system.
Falck, John R., Lombard, Julian H., Lukaszewicz, Kathleen M., Manthati, Vijaya L.   +3 more
core   +1 more source

Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing [PDF]

, 2019
PURPOSE: A number of institutions have clinically implemented CYP2D6 genotyping to guide drug prescribing. We compared implementation strategies of early adopters of CYP2D6 testing, barriers faced by both early adopters and institutions in the process
Beitelshees, Amber L., Bell, Gillian C., Bishop, Jeffrey R., Blake, Kathryn, Cavallari, Larisa H., Crona, Daniel J., Dressler, Lynn, Duong, Benjamin Q., Empey, Philip E., Gregg, Ryan A., Hicks, J. Kevin, Hines, Lindsay J., Johnson, Julie A., Lee, James C., Limdi, Nita A., Obeng, Aniwaa Owusu, Peterson, Josh F., Pratt, Victoria M., Prows, Cynthia A., Ramsey, Laura B., Scott, Stuart A., Shelton, Richard C., Skaar, Todd C., Smith, D. Max, Tuteja, Sony, Van Driest, Sara L., Weitzel, Kristin Wiisanen   +26 more
core   +1 more source

Clinical Significance of Drug–Drug Interaction Studies During Therapeutic Peptide Drug Development: Follow‐Up Investigation of Therapeutic Peptides Approved Between 2021 and 2024

Clinical and Translational Science, Volume 18, Issue 7, July 2025.
ABSTRACT The risk of clinically relevant drug–drug interactions (DDIs) for therapeutic peptides remains unclear, mandating a comprehensive analysis for this modality. In our prior study, we analyzed DDIs for 31 peptide drugs approved between January 2008 and August 2021.
Carolina Säll, Upendra Argikar, Constanze Hilgendorf, Hilmar Schiller, Anders Sonesson, Kenichi Umehara, Kai Wang   +6 more
wiley   +1 more source

Combining Genome Wide Association Studies and Differential Gene Expression Data Analyses Identifies Candidate Genes Affecting Mastitis Caused by Two Different Pathogens in the Dairy Cow [PDF]

, 2015
Mastitis is a costly disease which hampers the dairy industry. Inflammation of the mammary gland is commonly caused by bacterial infection, mainly Escherichia coli, Streptococcus uberis and Staphylococcus aureus.
Chen, X, Cheng, Z R, Wathes, D C, Werling, D, Zhang, S   +4 more
core   +3 more sources